Target intelligence / Profile preview

Transcription activator GLI1 (GLI1)

Target
GLI1
Molecular classification
Transcription factor, Zinc finger protein
01

Overview

Transcription activator GLI1 (also known as GLI proto-oncogene 1) is a zinc-finger transcription factor that serves as the terminal effector of the Hedgehog (Hh) signaling pathway. It plays a critical role in embryonic development, tissue patterning, and cell differentiation. In adult tissues, aberrant activation of GLI1—either through canonical ligand-dependent Hedgehog signaling or non-canonical pathways such as RAS-RAF-MEK-ERK and PI3K-AKT-mTOR—drives oncogenesis, tumor cell proliferation, metastasis, and chemotherapeutic resistance. GLI1 is highly expressed in various malignancies, including basal cell carcinoma, medulloblastoma, pancreatic cancer, and colorectal cancer. While upstream Smoothened (SMO) inhibitors like vismodegib indirectly suppress GLI1 activity, direct GLI1 inhibitors (such as GANT61 and Glabrescione B) and degraders (such as arsenic trioxide) are being actively investigated to overcome SMO-mediated resistance and non-canonical pathway activation.

Other names
GLI proto-oncogene 1Glioma-associated oncogene homolog 1Zinc finger protein GLI1GLI
02

Mechanism of action

Direct inhibition of GLI1-DNA binding (e.g., GANT61, Glabrescione B), promotion of GLI1 protein degradation (e.g., arsenic trioxide), or upstream inhibition of Smoothened (SMO) (e.g., vismodegib, sonidegib) to prevent GLI1 nuclear translocation and transcriptional activation.

03

Biological functions

Signal transductionCell proliferationCell cycleApoptosisTranscription regulationEmbryonic developmentCell differentiation
04

Disease associations

CancerBasal cell carcinomaMedulloblastomaGlioblastomaPancreatic cancerColorectal cancerAcute myeloid leukemia
05

Safety considerations

Off-target toxicity due to zinc-finger bindingImpairment of normal tissue homeostasis and embryonic developmentSkin toxicityDysgeusiaAlopeciaMuscle spasmsPotential for systemic toxicity when combined with other pathway inhibitors (e.g., PI3K inhibitors)
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

GLI1 mRNA expressionGLI1 nuclear localizationPTCH1 mRNA expressionPTCH1::GLI1 fusionACTB::GLI1 fusion

Beyond the preview

Go deeper on Transcription activator GLI1 (GLI1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcription activator GLI1 (GLI1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call